Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWT020 Alone and in Combination With Other Antitumor Therapies in Advanced Malignancies
NCT06839105Phase 1Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Apr 2028
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of AWT020 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC) and 3 more (5 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Dose-Limiting Toxicity rate at 12 months, Adverse Events at 12 months and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
AWT020
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)renal cell carcinoma (RCC)melanomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06839105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839105.